Skip to content

Efficacy and safety of Astragalus plus Notoginseng granule on type 2 diabetic nephropathy: the multi-centre randomized controlled trial

Efficacy and safety of Astragalus plus Notoginseng granule on type 2 diabetic nephropathy: the multi-centre randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023531
Enrollment
Unknown
Registered
2019-06-01
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephrology

Interventions

Sponsors

Shanghai Sixth People's Hospital East
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: It meets the diagnostic criteria of diabetic nephrology and traditional Chinese medicine syndrome of qi deficiency and blood stasis. Moreover, urinary microalbumin was 30-3000mg/d, eGFR was greater than 60ml/min/1.73m2 (stage 1-2 chronic kidney disease), and aged 18-75 years.

Exclusion criteria

Exclusion criteria: 1 Type 1 diabetes mellitus; 2 Patients with hyperglycemia caused by gestational diabetes, hyperthyroidism and other diseases; Accompanied by psychosis, senile dementia, etc. 3 Serious heart, brain, liver and other complications; Patients with malignant tumors, severe cardiac insufficiency, pregnancy, immune system diseases or other complications, and acute or chronic infections; 4 Patients who are known to be allergic to the drugs used; Who are participating in another clinical trial or who have participated in another clinical trial within 3 months.

Design outcomes

Primary

MeasureTime frame
24 h urinary protein quantification;ACR;Excretion of urine podocyte;podocalyxin;eGFR;renal function;

Secondary

MeasureTime frame
electrolyte;blood glucose;

Countries

China

Contacts

Public ContactDingkun Gui

Shanghai Sixth People's Hospital East

dick7837@163.com+86 18017579169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026